Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: Studies on cell-mediated immunity and humoral antibody response

A. Mantovani, F. Spreafico

Research output: Contribution to journalArticle

Abstract

C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.

Original languageEnglish
Pages (from-to)537-544
Number of pages8
JournalEuropean Journal of Cancer (1965)
Volume11
Issue number8
DOIs
Publication statusPublished - 1975

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: Studies on cell-mediated immunity and humoral antibody response'. Together they form a unique fingerprint.

  • Cite this